Photo from wikipedia
Key Points Question How frequently do immune checkpoint inhibitor (ICI) agents vs non-ICI agents qualify for American Society of Clinical Oncology Value Framework version 2 (ASCO-VF v2) tail-of-the-curve bonuses or… Click to show full abstract
Key Points Question How frequently do immune checkpoint inhibitor (ICI) agents vs non-ICI agents qualify for American Society of Clinical Oncology Value Framework version 2 (ASCO-VF v2) tail-of-the-curve bonuses or European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) immunotherapy-triggered long-term plateau adjustments? Findings In this cohort study of 100 randomized clinical trials comparing ICI with non-ICI agents, ASCO-VF v2 tail-of-the-curve bonuses and ESMO-MCBS v1.1 immunotherapy-triggered long-term plateau adjustments were not awarded to ICI agents more often than non-ICI agents. Meaning The ASCO-VF v2 and ESMO-MCBS v1.1 may be flawed in accurately capturing long-term survival.
Journal Title: JAMA Network Open
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!